Autoimmune - 2/7

Entry	Author	Date	Location
Tolerx, After a Decade and $150M, Eagerly Awaits Data from Big Diabetes Trial	Luke Timmerman	03/04/10	Boston
NanoString Chairman Bill Young Scopes Out Diagnostic Future, Considers Bay Area Expansion	Luke Timmerman	02/19/10	Seattle
Eleven Biotherapeutics Raises $35M, Seeks to Crank the Amplifer Up on Protein Drugs	Luke Timmerman	02/17/10	Boston
VentiRx Nabs $25M, Gilead Deepens Seattle Roots, Sage Strikes Deal With Pfizer & More Seattle-Area Life Sciences News	Luke Timmerman	01/14/10	Seattle
Lycera, a Midwestern Biotech Star, Moves Head Office to Boston, Hires Biogen Vet as CEO	Luke Timmerman	01/07/10	Boston
VLST Cuts Jobs To Preserve Cash, Still Feeding Novo Nordisk Pipeline	Luke Timmerman	12/22/09	Seattle
Biogen Idec’s Dream: Antibodies That Kill Two Birds With One Stone	Luke Timmerman	12/09/09	Boston
ZymoGenetics Sells Inflammatory Drug to Old Parent, Novo Nordisk, for $24M Upfront	Luke Timmerman	12/08/09	Seattle
Kineta Cuts Deal With MPI	Luke Timmerman	10/27/09	Seattle
Biotech Pioneer Steve Gillis on Life as a VC, How Today’s Entrepreneurs Can Make It, and Seattle’s Future in Life Sciences (Part 1)	Luke Timmerman	09/23/09	Seattle
Novo Nordisk’s Historic Mistake is Seattle’s Future Gain, Says Novo CEO	Luke Timmerman	09/18/09	Seattle
Zymo Drug Fails Arthritis Trials	Luke Timmerman	09/10/09	Seattle
Intellikine, Stocked With Cash, Pushes Portfolio of Drugs Against Biology’s Hot Targets	Luke Timmerman	08/18/09	San Diego
Avila Therapeutics Gets $30M to Push Ahead With Covalent Drugs	Luke Timmerman	07/27/09	Boston
ZymoGenetics Picks Up Mojo, Dendreon Looks Southeast, Cell Therapeutics Raises Dough & More Seattle-Area Life Sciences News	Luke Timmerman	07/23/09	Seattle
ZymoGenetics Picks Up Some of Human Genome Sciences’ Mojo With Lupus Drug	Luke Timmerman	07/21/09	Seattle
Targeted Genetics Dumps Lease, Amgen’s Dmab Works in Cancer Trial, Theraclone Nabs Cash, & More Seattle-Area Life Sciences News	Luke Timmerman	07/09/09	Seattle
Kineta Acquires Multiple Sclerosis, Diabetes Drug Candidates to Test Unusual Biotech Strategy	Luke Timmerman	07/08/09	Seattle
ASCO Weekend Recap: OncoGenex, Seattle Genetics, Vulcan-Backed BiPar Show Off Cancer Drug Results	Luke Timmerman	06/01/09	Seattle
Taligen Raises $26M For Inflammation Drugs	Luke Timmerman	05/12/09	Boston
Calistoga Raises $30M to Develop Drugs for Cancer, Inflammation	Luke Timmerman	05/05/09	Seattle
ZymoGenetics Cuts One-Third of Workforce To Hold Onto Cash	Luke Timmerman	04/29/09	Seattle
Biotech Neighbors, VLST and Novo Nordisk, Forge Alliance in Seattle’s South Lake Union	Luke Timmerman	04/06/09	Seattle
Trubion Starts Lupus Trial	Luke Timmerman	03/25/09	Seattle
Biogen Idec, Genentech’s Rituxan Fails in Pivotal Study of Lupus of Kidneys	Luke Timmerman	03/11/09	Boston
Dicerna Aims to Gain Foothold in RNAi World With More Potent, Longer-Lasting Gene Silencers	Luke Timmerman	01/30/09	Boston
Seattle Genetics Raises Dough, Trubion Feels Fallout of Pfizer Deal, Novo Sets Up Shop, & More Seattle-Area Life Sciences News	Luke Timmerman	01/29/09	Seattle
ZymoGenetics Takes Back Full Rights to Cancer Drug Candidate	Luke Timmerman	01/28/09	Seattle
Riding the Diabetes Wave, Novo Nordisk Sees Chance to Scoop Up Biotech Talent in Seattle	Luke Timmerman	01/28/09	Seattle
Pfizer’s Bid For Wyeth Sends Ripples Through Trubion Pharmaceuticals, Seattle Biotechs	Luke Timmerman	01/27/09	Seattle
Page 2 of 3	« previous page · next page »

Entry

Author

Date

Location

Tolerx, After a Decade and $150M, Eagerly Awaits Data from Big Diabetes Trial

Luke Timmerman

03/04/10

Boston

NanoString Chairman Bill Young Scopes Out Diagnostic Future, Considers Bay Area Expansion

Luke Timmerman

02/19/10

Seattle